RAZADYNE® ER is an acetylcholinesterase inhibitor (AChEI). RAZADYNE® ER is indicated for the treatment of mild to moderate dementia of the Alzheimer's type.
In a 6-month clinical trial comparing RAZADYNE® ER to placebo, patients treated with RAZADYNE® ER showed significant improvement in cognitive performance vs placebo as measured by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog/11). Patients treated with RAZADYNE® ER significantly improved in activities of daily living (ADLs)* vs placebo as measured by the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale. This was a secondary efficacy measure in this study.
RAZADYNE® ER may help patients by:
*"Activities of daily living" include eating, walking, using the restroom, bathing, grooming, dressing, physical performance, using common household appliances, conversation, tending to the home, managing personal belongings, travel, shopping, knowledge of current events, reading, and writing.9
Click the link to learn more about how RAZADYNE® ER can help your patients with Alzheimer's mild to moderate dementia of the Alzheimer's type.